John Crowley - Biotech's Chief Evangelist - [Art of Investing, EP.15] - Joys of Compounding Recap

Podcast: Joys of Compounding

Published: 2024-03-18

Duration: 5902

Guests: John Crowley

What Happened

John Crowley's life has parallels to superhero stories, with his family's journey depicted in the movie 'Extraordinary Measures'. His children were diagnosed with Pompe disease, which was untreatable at the time, prompting Crowley to enter the biotech industry to find a cure. The result was the development of enzyme replacement therapy, which has helped not only his children but many others.

Crowley's career in biotech includes founding Amicus Therapeutics and Novozyme, demonstrating significant success in the industry. Novozyme, started with $30,000 in seed capital, was acquired by Genzyme, yielding a 12x return to investors. Amicus continues to thrive with a market cap of $4 billion and two approved products for Fabry and Pompe diseases.

With a rich educational background, including time at the Naval Academy and Harvard Business School, Crowley emphasizes the importance of choosing institutions based on values and fit rather than purely academics. His time in the Navy Reserve and his leadership roles in biotech exhibit his dedication to service and innovation.

Crowley has recently been appointed CEO of the Biotechnology Innovation Organization (BIO), a leading advocacy group for biotech companies. His selection reflects his extensive experience and significant contributions to the industry. He continues to influence biotech policy and education on a global scale.

Biotech investing is characterized by its high risks and potential rewards, with top investments yielding up to 300% returns. Understanding the complexities of technology, regulation, and commercialization is crucial for success. Crowley shares insights into the importance of strong leadership and resilience in navigating these challenges.

The episode delves into the evolution of the biotech industry, from cell-based engineering in the 1970s to the genomics revolution in the 2000s, and now the promising developments in gene therapy and AI. The potential impact of AI in diagnostics, drug screening, and clinical trials is particularly highlighted.

Mergers and acquisitions (M&A) play a critical role in the biotech sector, with larger companies acquiring startups to accelerate the time-to-market for new medicines. This activity benefits patients, investors, and contributes to the industry's overall growth. The discussion also covers the transformation of obesity treatment through GLP-1 drugs, which have shown a good safety profile.

John Crowley's personal journey is intertwined with professional achievements, as seen in his daughter's blog 'High Heeled Wheels', where she shares her experiences living with Pompe disease. Megan Crowley has achieved academic success and works at the Make-A-Wish Foundation, exemplifying resilience and dedication amidst challenges.

Key Insights

• John Crowley's entry into biotech was driven by a personal mission to cure his children's Pompe disease, leading to the creation of enzyme replacement therapy. This therapy has significantly improved the lives of those affected by the disease.
• Amicus Therapeutics, founded by Crowley, has achieved a market cap of $4 billion and developed two approved products for rare diseases. It raised over $150 million in venture capital and went public, showcasing its financial growth and impact.
• Biotech investing involves high risks and rewards, with potential returns of up to 300% for top investments. Success requires a deep understanding of technology, regulation, and commercialization complexities.
• The biotechnology industry is undergoing its third revolution, driven by advancements in gene therapy and AI. AI is expected to enhance diagnostics, drug screening, and clinical trials, offering transformative potential for the sector.